
Finding New Opportunities In Obesity With Moonwalk Bioscience's Alex Aravanis, M.D., Ph.D.
Episode 324
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Alex Aravanis, M.D., Ph.D., CEO of Moonwalk Biosciences, talks about the opportunity in obesity beyond GLP-1s. He describes Moonwalk’s adipose-targeted siRNA strategy, the genetics-driven logic behind its targets, and what it takes to fund and build a clinical-stage company. Alex also discusses Moonwalk's recent $70 million Series B raise, using AI to prioritize targets and improve siRNA design, and how weight loss without appetite suppression could preserve lean muscle mass and improve tolerability. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Publisher
Business Of Biotech
Link
www.lifescienceleader.com/doc/finding-new-opportunities-in-obesity-with-moonwalk-bioscience-s-alex-aravanis-m-d-ph-d-0001
Published
September 21, 2026
Duration
47 min
Format
Podcast
Category
Issues · Business
Source
RSS feed
Host
Ben Comer
Business Of Biotech
@businessofbiotech
#finding #opportunities #moonwalkbiosciencesalex #management #lifesciences
